SWKH · Swk Holdings Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $10.88M | $10.05M | $11.83M | - | $10.42M | $11.54M | $11.78M | - | $8.96M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | $147.0K | $645.0K | $758.0K | - | $585.0K | $520.0K | $530.0K | - | $606.0K |
| SG&A | - | $3.29M | $2.84M | $3.28M | - | $2.99M | $2.92M | $2.68M | - | $2.98M |
| Total Operating Expenses | - | - | - | - | - | - | ($1.61M) | ($1.47M) | - | ($4.33M) |
| D&A | - | $2.0K | $421.0K | $19.0K | - | $652.0K | $421.0K | $514.0K | - | $652.0K |
| Operating Income | - | $6.68M | $4.63M | $1.08M | - | $4.08M | $5.43M | $1.09M | - | $4.09M |
| Interest Expense | - | - | - | $300.0K | - | $200.0K | $1.12M | $1.26M | - | $176.0K |
| Income Tax | - | $1.92M | $1.03M | $1.28M | - | $906.0K | $1.03M | $229.0K | - | ($386.0K) |
| Net Income | - | $8.78M | $3.54M | $4.54M | - | $3.47M | $4.39M | $861.0K | - | $4.47M |
| EPS - Basic | - | $0.72 | $0.29 | $0.37 | - | $0.28 | $0.35 | $0.07 | - | $0.36 |
| EPS - Diluted | - | $0.72 | $0.29 | $0.37 | - | $0.28 | $0.35 | $0.07 | - | $0.36 |
Balance Sheet
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $42.76M | $10.21M | $8.01M | $29.81M | $5.93M | $17.18M | $5.55M | $5.50M | $4.50M | $31.03M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $46.79M | $16.33M | $21.19M | $75.94M | $20.25M | $25.21M | $14.79M | $13.94M | $11.87M | $37.20M |
| Total Assets | $272.42M | $289.36M | $285.70M | $331.26M | $332.24M | $321.28M | $321.37M | $322.35M | $334.25M | $315.85M |
| Current Liabilities | $4.97M | $2.87M | $6.68M | $6.72M | $5.57M | $4.98M | $5.53M | $4.38M | $3.94M | $24.77M |
| Long-term Debt | $32.97M | $32.97M | $32.97M | $32.97M | $32.97M | $32.97M | $32.97M | $32.97M | $32.97M | - |
| Total Liabilities | $37.32M | $35.16M | $39.23M | $38.59M | $43.55M | $37.85M | $38.17M | $42.06M | $53.94M | $38.28M |
| Stockholders' Equity | $235.10M | $254.21M | $246.47M | $292.67M | $288.69M | $283.43M | $283.20M | $280.29M | $280.31M | $277.56M |
| Retained Earnings | ($4.18B) | ($4.16B) | ($4.17B) | ($4.13B) | ($4.13B) | ($4.14B) | ($4.14B) | ($4.14B) | ($4.14B) | ($4.15B) |
Cash Flow
| Line item | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | $8.28M | - | - | - | $4.43M | - | - |
| Investing Cash Flow | - | - | - | $22.70M | - | - | - | $9.18M | - | - |
| Financing Cash Flow | - | - | - | ($7.10M) | - | - | - | ($13.35M) | - | - |
| CapEx | - | - | - | $0 | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | $8.28M | - | - | - | - | - | - |
Ratios
| Metric | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | 61.3% | 46.1% | 9.1% | - | 39.2% | 47.0% | 9.3% | - | 45.6% |
| EBITDA margin | - | 61.4% | 50.2% | 9.3% | - | 45.4% | 50.7% | 13.6% | - | 52.9% |
| Net margin | - | 80.7% | 35.2% | 38.4% | - | 33.3% | 38.1% | 7.3% | - | 49.9% |
| Free cash flow margin | - | - | - | 70.0% | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 1.82 | - | - | - | - | - | - |
| R&D / Revenue | - | 1.4% | 6.4% | 6.4% | - | 5.6% | 4.5% | 4.5% | - | 6.8% |
| SG&A / Revenue | - | 30.2% | 28.3% | 27.7% | - | 28.7% | 25.3% | 22.8% | - | 33.2% |
| Effective tax rate | - | 17.9% | 22.5% | 22.0% | - | 20.7% | 19.1% | 21.0% | - | -9.4% |
| Return on assets | - | 3.0% | 1.2% | 1.4% | - | 1.1% | 1.4% | 0.3% | - | 1.4% |
| Return on equity | - | 3.5% | 1.4% | 1.6% | - | 1.2% | 1.6% | 0.3% | - | 1.6% |
| Return on invested capital | - | 1.9% | 1.3% | 0.3% | - | 1.0% | 1.4% | 0.3% | - | - |
| Liquidity | ||||||||||
| Current ratio | 9.41 | 5.68 | 3.17 | 11.30 | 3.64 | 5.06 | 2.68 | 3.18 | 3.01 | 1.50 |
| Quick ratio | 9.41 | 5.68 | 3.17 | 11.30 | 3.64 | 5.06 | 2.68 | 3.18 | 3.01 | 1.50 |
| Cash ratio | 8.60 | 3.55 | 1.20 | 4.44 | 1.07 | 3.45 | 1.00 | 1.26 | 1.14 | 1.25 |
| Leverage | ||||||||||
| Debt / Equity | 0.14 | 0.13 | 0.13 | 0.11 | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | - |
| Debt / Assets | 0.12 | 0.11 | 0.12 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | - |
| Debt / EBITDA | - | 4.94 | 6.53 | 30.03 | - | 6.96 | 5.63 | 20.55 | - | - |
| Interest coverage | - | - | - | 3.6x | - | 20.4x | 4.9x | 0.9x | - | 23.2x |
| Equity multiplier | 1.16 | 1.14 | 1.16 | 1.13 | 1.15 | 1.13 | 1.13 | 1.15 | 1.19 | 1.14 |
| Liabilities / Assets | 0.14 | 0.12 | 0.14 | 0.12 | 0.13 | 0.12 | 0.12 | 0.13 | 0.16 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.04 | 0.04 | 0.04 | - | 0.03 | 0.04 | 0.04 | - | 0.03 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | 4.5% | -12.9% | 0.4% | - | 16.2% | 21.5% | 25.2% | - | -34.2% |
| Revenue CAGR (3y) | - | -7.2% | 13.1% | 2.1% | - | 2.9% | -19.7% | 7.9% | - | -5.6% |
| Revenue CAGR (5y) | - | 0.4% | 4.9% | 10.1% | - | 10.4% | 15.3% | 4.6% | - | 8.8% |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 63.5% | -14.8% | -1.0% | - | -0.1% | 0.8% | -75.9% | - | -39.5% |
| Net income growth (YoY) | - | 153.2% | -19.5% | 427.2% | - | -22.5% | 11.7% | -81.4% | - | -32.4% |
| EPS growth (YoY) | - | 157.1% | -17.1% | 428.6% | - | -22.2% | 12.9% | -80.6% | - | -29.4% |
| EPS CAGR (3y) | - | 12.2% | 93.5% | 11.1% | - | 18.1% | -31.5% | -35.4% | - | 1.9% |
| EPS CAGR (5y) | - | 16.2% | 32.9% | - | - | -2.6% | 0.6% | -32.8% | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -18.6% | -10.3% | -13.0% | 4.4% | 3.0% | 2.1% | 3.4% | 2.2% | 0.1% | 0.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.15M totalPharmaceutical Development Segment$2.15M · 100.0%
Product / service
$2.15M totalPharmaceutical Development$2.15M · 100.0%
Peer comparison
Same SIC group: Miscellaneous Business Credit Institution
| Company | Revenue (last FY) | Net margin | ROE |
|---|---|---|---|
| SPFX | $12.47M | 9.7% | 14.3% |
Comparing SWK Holdings Corp against the 1 most active filer in the same SIC group.